» Articles » PMID: 2190938

Characterization of a 90-100 KDa Tumor-associated Antigen in the Sera of Melanoma Patients

Overview
Journal Int J Cancer
Specialty Oncology
Date 1990 Jun 15
PMID 2190938
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Using allogeneic antibody, we previously described a high-molecular-weight glycoprotein in the urine of 68% of melanoma patients. This glycoprotein has been termed urinary-tumor-associated antigen (U-TAA). A murine monoclonal antibody (MAb) specific for U-TAA (ADI-40F4) has been developed. By the use of ADI-40F4, U-TAA was detected in serum samples from 63% (33/52) of stage II and stage III melanoma patients, but from only 5% (1/20) of normal controls. This report describes the physical and immunochemical properties of U-TAA in the serum. The antigen elutes from a DEAE-Sephacel column in association with IgG in the void volume and as free antigen in a second peak. The molecular mass of the free antigen is 590-620 kDa and it sediments in the region of 28-29% sucrose by density gradient ultracentrifugation. Free antigen has an isoelectric point of 6.1. This high molecular weight antigen is composed of smaller subunits linked by reducible bonds. The ADI-40F4 reactive epitope resides on a 90-100 kDa subunit. These results provide evidence that U-TAA which is produced by melanoma cells in vitro is present in the circulation of melanoma patients.

Citing Articles

Noncytolytic inhibition of X4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines.

Kursar M, Brown N, Kerr E, Luster A, Walker B J Virol. 2001; 75(17):8306-16.

PMID: 11483776 PMC: 115075. DOI: 10.1128/jvi.75.17.8306-8316.2001.


Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.

Jones R, Kelley M, Gupta R, Nizze J, Yee R, Leopoldo Z Ann Surg Oncol. 1996; 3(5):437-45.

PMID: 8876885 DOI: 10.1007/BF02305761.


Melanoma vaccines. Current status and future prospects.

Hersey P Drugs. 1994; 47(3):373-82.

PMID: 7514970 DOI: 10.2165/00003495-199447030-00001.


Association between allo-immunoreactive and xeno-immunoreactive subunits of a glycoprotein tumor-associated antigen.

Euhus D, Gupta R, Morton D Cancer Immunol Immunother. 1990; 32(4):214-20.

PMID: 1702032 PMC: 11038802. DOI: 10.1007/BF01741703.


Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen.

Hunt K, Shibata M, Gupta R, Morton D Cancer Immunol Immunother. 1992; 34(6):377-82.

PMID: 1563014 PMC: 11038076. DOI: 10.1007/BF01741747.